639 related articles for article (PubMed ID: 25608569)
21. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
Reddy ND; Shoja MH; Biswas S; Nayak PG; Kumar N; Rao CM
Chem Biol Interact; 2016 Jun; 253():112-24. PubMed ID: 27163855
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Greve G; Schiffmann I; Lübbert M
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188
[TBL] [Abstract][Full Text] [Related]
23. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
24. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
[TBL] [Abstract][Full Text] [Related]
25. Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.
Pradhan S; Mahajan D; Kaur P; Pandey N; Sharma C; Srivastava T
Oncotarget; 2016 Nov; 7(44):71841-71855. PubMed ID: 27708247
[TBL] [Abstract][Full Text] [Related]
26. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Luszczek W; Cheriyath V; Mekhail TM; Borden EC
Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
[TBL] [Abstract][Full Text] [Related]
27. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
Jeon YJ; Ko SM; Cho JH; Chae JI; Shim JH
Int J Mol Med; 2013 Oct; 32(4):860-6. PubMed ID: 23877235
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Singh T; Prasad R; Katiyar SK
Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
[TBL] [Abstract][Full Text] [Related]
29. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia.
Aquino-Gálvez A; González-Ávila G; Delgado-Tello J; Castillejos-López M; Mendoza-Milla C; Zúñiga J; Checa M; Maldonado-Martínez HA; Trinidad-López A; Cisneros J; Torres-Espíndola LM; Hernández-Jiménez C; Sommer B; Cabello-Gutiérrez C; Gutiérrez-González LH
Oncol Rep; 2016 Jan; 35(1):577-83. PubMed ID: 26548300
[TBL] [Abstract][Full Text] [Related]
30. Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.
To KKW; Cheung KM; Cho WCS
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7217-7234. PubMed ID: 36905422
[TBL] [Abstract][Full Text] [Related]
31. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
Cai Y; Yan X; Zhang G; Zhao W; Jiao S
Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
[TBL] [Abstract][Full Text] [Related]
32. Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
Pflieger M; Hamacher A; Öz T; Horstick-Muche N; Boesen B; Schrenk C; Kassack MU; Kurz T
Bioorg Med Chem; 2019 Oct; 27(19):115036. PubMed ID: 31431326
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer.
Salaroglio IC; Belisario DC; Akman M; La Vecchia S; Godel M; Anobile DP; Ortone G; Digiovanni S; Fontana S; Costamagna C; Rubinstein M; Kopecka J; Riganti C
J Exp Clin Cancer Res; 2022 Aug; 41(1):243. PubMed ID: 35953814
[TBL] [Abstract][Full Text] [Related]
34. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
35. Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer.
Yang N; Liang Y; Yang P; Ji F
Oncol Rep; 2017 May; 37(5):2611-2619. PubMed ID: 28426124
[TBL] [Abstract][Full Text] [Related]
36. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
37. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
Li F; Wang T; Wang Z; Chen X; Liu R
Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
[TBL] [Abstract][Full Text] [Related]
39. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
40. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
Hu H; Miao XK; Li JY; Zhang XW; Xu JJ; Zhang JY; Zhou TX; Hu MN; Yang WL; Mou LY
Eur J Pharmacol; 2020 May; 874():172961. PubMed ID: 32044322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
